BACKGROUND: Renal cell carcinoma is difficult to diagnose and unpredictable in disease course and severity. There are no specific biomarkers for diagnosis and prognosis estimation feasible in clinical practice. Long non-coding RNAs (lncRNAs) have emerged as potent regulators of gene expression in recent years. Aside from their cellular role, their expression patterns could be used as a biomarker of ongoing pathology. METHODS: In this work, we used next-generation sequencing for global lncRNA expression profiling in tumor and non-tumor tissue of RCC patients. The four candidate lncRNAs have been further validated on an independent cohort. PVT1, as the most promising lncRNA, has also been studied using functional in vitro tests. RESULTS: Next-generation sequencing showed significant dysregulation of 1163 lncRNAs; among them top 20 dysregulated lncRNAs were AC061975.7, AC124017.1, AP000696.1, AC148477.4, LINC02437, GATA3-AS, LINC01762, LINC01230, LINC01271, LINC01187, LINC00472, AC007849.1, LINC00982, LINC01543, AL031710.1, and AC019197.1 as down-regulated lncRNAs; and SLC16A1-AS1, PVT1, LINC0887, and LUCAT1 as up-regulated lncRNAs. We observed statistically significant dysregulation of PVT1, LUCAT1, and LINC00982. Moreover, we studied the effect of artificial PVT1 decrease in renal cell line 786-0 and observed an effect on cell viability and migration. CONCLUSION: Our results show not only the diagnostic but also the therapeutic potential of PVT1 in renal cell carcinoma.

Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Biology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Pharmacology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Urologic Oncology Department of Comprehensive Cancer Care Faculty of Medicine Masaryk Memorial Cancer Institute Masaryk University Brno Czech Republic

Department of Urology The University Hospital Brno Faculty of Medicine Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209‐249. PubMed

Campi R, Stewart GD, Staehler M, et al. Novel liquid biomarkers and innovative imaging for kidney cancer diagnosis: what can be implemented in our practice today? A systematic review of the literature. Eur Urol Oncol. 2021;4(1):22‐41. PubMed

Peng W‐X, Koirala P, Mo Y‐Y. LncRNA‐mediated regulation of cell signaling in cancer. Oncogene. 2017;36(41):5661‐5667. PubMed PMC

Chen J, Chen Y, Gu L, et al. LncRNAs act as prognostic and diagnostic biomarkers in renal cell carcinoma: a systematic review and meta‐analysis. Oncotarget. 2016;7(45):74325‐74336. PubMed PMC

Lorenzen JM, Thum T. Long noncoding RNAs in kidney and cardiovascular diseases. Nat Rev Nephrol. 2016;12(6):360‐373. PubMed

Ricketts CJ, De Cubas AA, Fan H, et al. The Cancer Genome Atlas Comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23(1):313‐326.e5. PubMed PMC

Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010; http://www.bioinformatics.babraham.ac.uk/projects/fastqc

Davis MPA, van Dongen S, Abreu‐Goodger C, Bartonicek N, Enright AJ. Kraken: a set of tools for quality control and analysis of high‐throughput sequence data. Methods. 2013;63(1):41‐49. PubMed PMC

Martin M. Cutadapt removes adapter sequences from high‐throughput sequencing reads. EMBnet J. 2011;17(1):10‐12.

Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA‐seq aligner. Bioinformatics. 2013;29(1):15‐21. PubMed PMC

Li B, Dewey CN. RSEM: accurate transcript quantification from RNA‐Seq data with or without a reference genome. BMC Bioinform. 2011;12:323. PubMed PMC

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA‐seq data with DESeq2. Genome Biol. 2014;15(12):550. PubMed PMC

Ding J, Li D, Gong M, et al. Expression and clinical significance of the long non‐coding RNA PVT1 in human gastric cancer. OncoTargets Ther. 2014;7:1625‐1630. PubMed PMC

Kong R, Zhang E, Yin D, et al. Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol Cancer. 2015;14:82. PubMed PMC

Zhuang C, Li J, Liu Y, et al. Tetracycline‐inducible shRNA targeting long non‐coding RNA PVT1 inhibits cell growth and induces apoptosis in bladder cancer cells. Oncotarget. 2015;6(38):41194‐41203. PubMed PMC

Iden M, Fye S, Li K, Chowdhury T, Ramchandran R, Rader JS. The lncRNA PVT1 contributes to the cervical cancer phenotype and associates with poor patient prognosis. PLoS One. 2016;11(5):e0156274. PubMed PMC

Zheng X, Hu H, Li S. High expression of lncRNA PVT1 promotes invasion by inducing epithelial‐to‐mesenchymal transition in esophageal cancer. Oncol Lett. 2016;12(4):2357‐2362. PubMed PMC

Yang Y‐R, Zang S‐Z, Zhong C‐L, Li Y‐X, Zhao S‐S, Feng X‐J. Increased expression of the lncRNA PVT1 promotes tumorigenesis in non‐small cell lung cancer. Int J Clin Exp Pathol. 2014;7(10):6929‐6935. PubMed PMC

Cui D, Yu C‐H, Liu M, Xia Q‐Q, Zhang Y‐F, Jiang W‐L. Long non‐coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non‐small cell lung cancer. Tumour Biol. 2016;37(3):4127‐4134. PubMed

Takahashi Y, Sawada G, Kurashige J, et al. Amplification of PVT‐1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer. 2014;110(1):164‐171. PubMed PMC

Posa I, Carvalho S, Tavares J, Grosso AR. A pan‐cancer analysis of MYC‐PVT1 reveals CNV‐unmediated deregulation and poor prognosis in renal carcinoma. Oncotarget. 2016;7(30):47033‐47041. PubMed PMC

Wu Q, Yang F, Yang Z, et al. Long noncoding RNA PVT1 inhibits renal cancer cell apoptosis by up‐regulating Mcl‐1. Oncotarget. 2017;8(60):101865‐101875. PubMed PMC

Bao X, Duan J, Yan Y, et al. Upregulation of long noncoding RNA PVT1 predicts unfavorable prognosis in patients with clear cell renal cell carcinoma. Cancer Biomark. 2017;21(1):55‐63. PubMed

Li W, Zheng Z, Chen H, Cai Y, Xie W. Knockdown of long non‐coding RNA PVT1 induces apoptosis and cell cycle arrest in clear cell renal cell carcinoma through the epidermal growth factor receptor pathway. Oncol Lett. 2018;15(5):7855‐7863. PubMed PMC

Bohosova J, Kubickova A, Slaby O. lncRNA PVT1 in the pathogenesis and clinical management of renal cell carcinoma. Biomolecules. 2021;11(5):664. PubMed PMC

Xiao H, Bao L, Xiao W, et al. Long non‐coding RNA Lucat1 is a poor prognostic factor and demonstrates malignant biological behavior in clear cell renal cell carcinoma. Oncotarget. 2017;8(69):113622‐113634. PubMed PMC

Wang L‐N, Zhu X‐Q, Song X‐S, Xu Y. Long noncoding RNA lung cancer associated transcript 1 promotes proliferation and invasion of clear cell renal cell carcinoma cells by negatively regulating miR‐495‐3p. J Cell Biochem. 2018;119(9):7599‐7609. PubMed

Zheng Z, Zhao F, Zhu D, et al. Long non‐coding RNA LUCAT1 promotes proliferation and invasion in clear cell renal cell carcinoma through AKT/GSK‐3β signaling pathway. Cell Physiol Biochem. 2018;48(3):891‐904. PubMed

Wang X, Ou H, Zhou L, Liu H, Liu X, Zhang H. Long non‐coding RNA LUCAT1 promotes the progression of clear cell renal cell carcinoma via the microRNA‐375/YAP1 axis. Exp Ther Med. 2021;22(1):754. PubMed PMC

Sun Y, Jin S‐D, Zhu Q, et al. Long non‐coding RNA LUCAT1 is associated with poor prognosis in human non‐small lung cancer and regulates cell proliferation via epigenetically repressing p21 and p57 expression. Oncotarget. 2017;8(17):28297‐28311. PubMed PMC

Gao Y‐S, Liu X‐Z, Zhang Y‐G, Liu X‐J, Li L‐Z. Knockdown of long noncoding RNA LUCAT1 inhibits cell viability and invasion by regulating miR‐375 in glioma. Oncol Res. 2018;26(2):307‐313. PubMed PMC

Yoon J‐H, You B‐H, Park CH, Kim YJ, Nam J‐W, Lee SK. The long noncoding RNA LUCAT1 promotes tumorigenesis by controlling ubiquitination and stability of DNA methyltransferase 1 in esophageal squamous cell carcinoma. Cancer Lett. 2018;417:47‐57. PubMed

Lou Y, Yu Y, Xu X, et al. Long non‐coding RNA LUCAT1 promotes tumourigenesis by inhibiting ANXA2 phosphorylation in hepatocellular carcinoma. J Cell Mol Med. 2019;23(3):1873‐1884. PubMed PMC

Fei Z‐H, Yu X‐J, Zhou M, Su H‐F, Zheng Z, Xie C‐Y. Upregulated expression of long non‐coding RNA LINC00982 regulates cell proliferation and its clinical relevance in patients with gastric cancer. Tumour Biol. 2016;37(2):1983‐1993. PubMed

Lv W, Yu X, Li W, et al. Low expression of LINC00982 and PRDM16 is associated with altered gene expression, damaged pathways and poor survival in lung adenocarcinoma. Oncol Rep. 2018;40(5):2698‐2709. PubMed

Zhang C, Li X‐Y, Luo Z‐Z, Wu T‐W, Hu H. Upregulation of LINC00982 inhibits cell proliferation and promotes cell apoptosis by regulating the activity of PI3K/AKT signaling pathway in renal cancer. Eur Rev Med Pharmacol Sci. 2019;23(4):1443‐1450. PubMed

Yang T, Zhou H, Liu P, et al. lncRNA PVT1 and its splicing variant function as competing endogenous RNA to regulate clear cell renal cell carcinoma progression. Oncotarget. 2017;8(49):85353‐85367. PubMed PMC

Long non-coding RNAs enable precise diagnosis and prediction of early relapse after nephrectomy in patients with renal cell carcinoma